For ongoing clinical trial information: NCT06302426
Every year, cancer claims the lives of more than half a million Americans and is the second leading cause of death in the United States. While checkpoint inhibitors and other novel immunotherapies have resulted in increased life expectancy for some people, current immunotherapies still fail in nearly 80% of cancer patients.
At Inimmune, we are using our expertise in innate immunity to produce new therapeutics to treat cancer. Our current clinical-stage cancer therapeutic is INI-4001, a potent TLR7/8 agonist that has been optimized for nanoparticle delivery. INI-4001 demonstrates efficacy as monotherapy and in combination with immune checkpoint therapy (ICT), such as anti-PD-1, in multiple pre-clinical murine cancer models. Our optimized nanoparticle formulation for INI-4001 enhances anti-tumor efficacy, maintaining high IFNα production while reducing pro-inflammatory TNFα. Mechanistically, INI-4001 increases the number of APCs and enhances CD8 T cell responses in the tumor microenvironment. We enrolled our first patient in our Phase I clinical trial using INI-4001 in solid tumor cancer indications started in July 2024. This is an open-label, all solid tumor trial investigating the safety of INI-4001 alone and in combination with various checkpoint inhibitors that will also result in preliminary efficacy data. To learn more about our ongoing clinical trial, please visit www.clinicaltrials.gov.
In our pre-clinical pipeline, we are exploring novel compounds targeting other innate immune receptors, such as STING and CLRs, as well as advanced delivery systems to target immunotherapy directly to the tumor and tumor microenvironment.
